Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 13/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | OGT | O15294 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2482363 | 0.98 | GRM5 (0.66) | GRM5EPHX2PBRM1MCL1OGT | |
| 4-Acetyl-2-Benzoxazolinone SCHEMBL3546681 | 0.83 | GRM5 (0.64) | GRM5EPHX2MCL1OGT | |
| Lithium Ion SCHEMBL1005730 | 0.81 | GRM5 (0.58) | GRM5EPHX2MCL1OGT | |
| SCHEMBL1005310 | 0.81 | PSMB8 (0.57) | GRM5PBRM1TDP1KEAP1 | |
| SCHEMBL1004904 | 0.79 | GRM5 (0.60) | GRM5EPHX2 | |
| SCHEMBL465947 | 0.78 | PBRM1 (0.54) | GRM5PBRM1MCL1TDP1KEAP1 | |
| SCHEMBL27371230 | 0.75 | GRM5 (0.53) | GRM5EPHX2 | |
| SCHEMBL1137634 | 0.74 | PSMB8 (0.61) | GRM5EPHX2MCL1OGT | |
| SCHEMBL31434922 | 0.73 | GRM5 (0.50) | GRM5 | |
| SCHEMBL3043379 | 0.71 | MCL1 (0.49) | GRM5EPHX2MCL1OGT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863271-B2 | 2-aminobenzoxazole carboxamides as 5HT3 modulators | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| EP-2061460-A2 | 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | Albany Molecular Research, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080255114-A1 | 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | AMR TECHNOLOGY, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| WO-2008019372-A2 | 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | ALBANY MOLECULAR RESEARCH, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255114-A1 | 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | HTR3E, HTR3C, HTR3A | GRM5 237/4885EPHX2 3170/4885PBRM1 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.